Kynexis Overview
- Year Founded
-
2023
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$112M
- Investors
-
4
Kynexis General Information
Description
Developer of a precision medicine intended for the treatment of cognitive impairment associated with schizophrenia. The company offers a human biology-based approach for its target rationale, a causal biomarker approach to establish its mechanism of action in clinical development, and a human genetics approach to identify responder subpopulations, enabling patients suffering from schizophrenia to restore their brain function.
Contact Information
Website
www.kynexistx.comCorporate Office
- Gooimeer 2-35
- 1411 DC Naarden
- Netherlands
Corporate Office
- Gooimeer 2-35
- 1411 DC Naarden
- Netherlands
Kynexis Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series A) | 19-Aug-2026 | $112M | Completed | Startup |
Kynexis Comparisons
Industry
Financing
Details
Kynexis Competitors (26)
One of Kynexis’s 26 competitors is MiNA Therapeutics, a Venture Capital-Backed company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| MiNA Therapeutics | Venture Capital-Backed | London, United Kingdom | ||||
| Bridge Medicines | Venture Capital-Backed | New York, NY | ||||
| EyePoint | Corporation | Watertown, MA | ||||
| Kinomica | Venture Capital-Backed | Macclesfield, United Kingdom | ||||
| Stemina Biomarker Discovery | Venture Capital-Backed | Madison, WI |
Kynexis Signals
Kynexis Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Forbion | Venture Capital | Minority | ||
| Novartis Venture Fund | Corporate Venture Capital | Minority | ||
| Sunstone Life Science Ventures | Venture Capital | Minority | ||
| Ysios Capital | Venture Capital | Minority |
Kynexis FAQs
-
When was Kynexis founded?
Kynexis was founded in 2023.
-
Where is Kynexis headquartered?
Kynexis is headquartered in Naarden, Netherlands.
-
What is the size of Kynexis?
Kynexis has 20 total employees.
-
What industry is Kynexis in?
Kynexis’s primary industry is Drug Discovery.
-
Is Kynexis a private or public company?
Kynexis is a Private company.
-
What is Kynexis’s current revenue?
The current revenue for Kynexis is .
-
How much funding has Kynexis raised over time?
Kynexis has raised $112M.
-
Who are Kynexis’s investors?
Forbion, Novartis Venture Fund, Sunstone Life Science Ventures, and Ysios Capital have invested in Kynexis.
-
Who are Kynexis’s competitors?
MiNA Therapeutics, Bridge Medicines, EyePoint, Kinomica, and Stemina Biomarker Discovery are some of the 26 competitors of Kynexis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process